WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994000148) SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/000148    International Application No.:    PCT/US1993/005906
Publication Date: 06.01.1994 International Filing Date: 18.06.1993
Chapter 2 Demand Filed:    10.01.1994    
IPC:
A61K 39/00 (2006.01), C07K 14/705 (2006.01)
Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; c/o Weizmann Institute of Science, P.O. Box 95, 76 100 Rehovot (IL).
McINNIS, Patricia, A. [US/US]; (US) (VN only)
Inventors: SELA, Michael; (IL).
MOZES, Edna; (IL)
Agent: BROWDY, Roger, L.; Browdy and Neimark, 419 Seventh Street, Suite 300, N.W., Washington, DC 20004 (US)
Priority Data:
900,393 18.06.1992 US
Title (EN) SYNTHETIC PEPTIDES FOR THE TREATMENT OF MYASTHENIA GRAVIS
(FR) PEPTIDES SYNTHETIQUES POUR LE TRAITEMENT DE LA MYASTHENIE GRAVE
Abstract: front page image
(EN)Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor $g(a)-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.
(FR)L'invention concerne des peptides comprenant au moins neuf résidus d'acides aminés contenant chacun une séquence d'acides aminés qui correspond à la position p200-208 ou p262-266 de la sous-unité $g(a) du récepteur d'acétylcholine humaine, mais qui diffère de cette dernière par une ou plusieurs substitutions d'acides aminés. Ces peptides inhibent la réponse proliférative des lymphocytes du sang périphérique aux peptides myasthogènes p195-212 et p259-271 et sont appropriés au traitement de sujets atteints de myasthénie grave.
Designated States: AU, CA, JP, VN.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)